Day One Biopharmaceuticals Stock Odds of Future Stock Price Finishing Over 13.35
| DAWN Stock | USD 13.72 0.38 2.85% |
Day |
Day One Target Price Odds to finish over 13.35
The tendency of Day Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 13.35 in 90 days |
| 13.72 | 90 days | 13.35 | about 92.38 |
Based on a normal probability distribution, the odds of Day One to stay above $ 13.35 in 90 days from now is about 92.38 (This Day One Biopharmaceuticals probability density function shows the probability of Day Stock to fall within a particular range of prices over 90 days) . Probability of Day One Biopharmaceu price to stay between $ 13.35 and its current price of $13.72 at the end of the 90-day period is about 11.82 .
Given the investment horizon of 90 days Day One has a beta of 0.91 suggesting Day One Biopharmaceuticals market returns are highly reactive to returns on the market. As the market goes up or down, Day One is expected to follow. Additionally Day One Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Day One Price Density |
| Price |
Predictive Modules for Day One
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Day One Biopharmaceu. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Day One's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Day One Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Day One is not an exception. The market had few large corrections towards the Day One's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Day One Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Day One within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 0.65 | |
Ir | Information ratio | -0.04 |
Day One Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Day One for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Day One Biopharmaceu can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Day One Biopharmaceu generated a negative expected return over the last 90 days | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research ... |
Day One Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Day Stock often depends not only on the future outlook of the current and potential Day One's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Day One's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 79.8 M | |
| Cash And Short Term Investments | 366.3 M |
Day One Technical Analysis
Day One's future price can be derived by breaking down and analyzing its technical indicators over time. Day Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Day One Biopharmaceuticals. In general, you should focus on analyzing Day Stock price patterns and their correlations with different microeconomic environments and drivers.
Day One Predictive Forecast Models
Day One's time-series forecasting models is one of many Day One's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Day One's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Day One Biopharmaceu
Checking the ongoing alerts about Day One for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Day One Biopharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Day One Biopharmaceu generated a negative expected return over the last 90 days | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research ... |
Check out Day One Backtesting, Day One Valuation, Day One Correlation, Day One Hype Analysis, Day One Volatility, Day One History as well as Day One Performance. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.